Show simple item record

Is race or ethnicity associated with under- utilization of statins among women in the United States: The study of women’s health across the nation

dc.contributor.authorJackson, Elizabeth A.
dc.contributor.authorRuppert, Kristine
dc.contributor.authorDerby, Carol A.
dc.contributor.authorLian, Yinjuan
dc.contributor.authorChae, Claudia U.
dc.contributor.authorKazlauskaite, Rasa
dc.contributor.authorNeal‐perry, Genevieve
dc.contributor.authorEl Khoudary, Samar R.
dc.contributor.authorHarlow, Siobán D.
dc.contributor.authorSolomon, Daniel H.
dc.date.accessioned2021-01-05T18:46:43Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2021-01-05T18:46:43Z
dc.date.issued2020-12
dc.identifier.citationJackson, Elizabeth A.; Ruppert, Kristine; Derby, Carol A.; Lian, Yinjuan; Chae, Claudia U.; Kazlauskaite, Rasa; Neal‐perry, Genevieve ; El Khoudary, Samar R.; Harlow, Siobán D. ; Solomon, Daniel H. (2020). "Is race or ethnicity associated with under- utilization of statins among women in the United States: The study of women’s health across the nation." Clinical Cardiology 43(12): 1388-1397.
dc.identifier.issn0160-9289
dc.identifier.issn1932-8737
dc.identifier.urihttps://hdl.handle.net/2027.42/163875
dc.description.abstractBackgroundRates of statin use among minority women are unclear.HypothesisWe hypothesized that statin use would vary by race/ethnicity with lower rates among minority women compared with Whites.MethodsData from the study of women’s health across the nation, a multiethnic cohort of women collected between 2009 to 2011 were used to examine reported statin use by race/ethnicity and risk profile. Multivariable logistic modeling was performed to estimate the odds ratio (OR) of statin treatment.ResultsOf the 2399 women included, 234 had a diagnosis of atherosclerotic disease (ASCVD), 254 were diabetic (without ASCVD), 163 had an LDL - ¥190- mg/dL, and 151 had a 10 year ASCVD pooled risk score - ¥7.5%. Statins were used by 49.6% of women with CVD; 59.8% of women with diabetes without known ASCVD; 42.3% of women with an LDL - ¥190- mg/dL; and 19.9% of women with an ASCVD risk - ¥7.5%. Rates of statin use were 43.8% for women with - ¥ two prior ASCVD events and 69.4% for women with - ¥ one prior ASCVD event plus multiple high- risk conditions. Among women eligible for statins, Black women had a significantly reduced adjusted odds of being on a statin (OR 0.53, 95% confidence interval [CI] 0.36- 0.78) compared with White women.ConclusionsIn this cohort of multiethnic women, rates of statin use among women who would benefit were low, with Black women having lower odds of statin use than White women.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherrace/ethnicity
dc.subject.otherstatin therapy
dc.subject.otherwomen
dc.subject.othercardiovascular prevention
dc.titleIs race or ethnicity associated with under- utilization of statins among women in the United States: The study of women’s health across the nation
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialities
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163875/1/clc23448_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163875/2/clc23448.pdf
dc.identifier.doi10.1002/clc.23448
dc.identifier.sourceClinical Cardiology
dc.identifier.citedreferenceSalami JA, Warraich H, Valero- Elizondo J, et al. National Trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the medical expenditure panel survey. JAMA Cardiol. 2017; 2 ( 1 ): 56 - 65.
dc.identifier.citedreferenceLloyd- Jones DM, Goff DC Jr, Stone NJ. Guidelines for cardiovascular risk assessment and cholesterol treatment. JAMA. 2014; 311 ( 21 ): 2235.
dc.identifier.citedreferenceGoff DC Jr, Lloyd- Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2014; 129 ( 25 ): S49 - S73.
dc.identifier.citedreferenceLahoud R, Howe M, Krishnan SM, Zacharias S, Jackson EA. Effect of use of combination evidence- based medical therapy after acute coronary syndromes on long- term outcomes. Am J Cardiol. 2012; 109 ( 2 ): 159 - 164.
dc.identifier.citedreferenceMosca L, Benjamin EJ, Berra K, et al. Effectiveness- based guidelines for the prevention of cardiovascular disease in women- 2011 update: a guideline from the american heart association. Circulation. 2011; 123 ( 11 ): 1243 - 1262.
dc.identifier.citedreferenceRamanath VS, Armstrong DF, Grzybowski M, et al. Receipt of cardiac medications upon discharge among men and women with acute coronary syndrome and nonobstructive coronary artery disease. Clin Cardiol. 2010; 33 ( 1 ): 36 - 41.
dc.identifier.citedreferenceZhao M, Woodward M, Vaartjes I, et al. Sex differences in cardiovascular medication prescription in primary care: a systematic review and meta- analysis. J Am Heart Assoc. 2020; 9 ( 11 ): e014742.
dc.identifier.citedreferenceSowers MFR, Crawford SL, Sternfeld B, et al SWAN: A Multicenter, Multiethnic, Community- Based Cohort Study of Women and the Menopausal Transition. In: Lobos RA, Kelsey J, Marcus R, eds. Menopause: biology and pathobiology. New York, NY: Academic Press 2000; 175 - 188.
dc.identifier.citedreferenceSteiner PFJBWSEA. Standardization of micromethods for plasma cholesterol, triglyceride and HDL- cholesterol with the lipid clinics’ methodology. J Clin Chem Biochem. 1981; 19: 850.
dc.identifier.citedreferenceWarnick GR, Albers JJ. A comprehensive evaluation of the heparin- manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res. 1978; 19 ( 1 ): 65 - 76.
dc.identifier.citedreferenceGrundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the Management of Blood Cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019; 73 ( 24 ): 3168 - 3209.
dc.identifier.citedreferenceMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high- risk individuals: a randomised placebo- controlled trial. Lancet. 2002; 360 ( 9326 ): 7 - 22.
dc.identifier.citedreferenceBugiardini R, Yan AT, Yan RT, et al. Factors influencing underutilization of evidence- based therapies in women. Eur Heart J. 2011; 32 ( 11 ): 1337 - 1344.
dc.identifier.citedreferenceVaccarino V, Rathore SS, Wenger NK, et al. Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002. N Engl J Med. 2005; 353 ( 7 ): 671 - 682.
dc.identifier.citedreferenceZhang H, Plutzky J, Shubina M, Turchin A. Drivers of the sex disparity in statin therapy in patients with coronary artery disease: a cohort study. PLoS One. 2016; 11 ( 5 ): e0155228.
dc.identifier.citedreferenceTang L, Patao C, Chuang J, Wong ND. Cardiovascular risk factor control and adherence to recommended lifestyle and medical therapies in persons with coronary heart disease (from the National Health and nutrition examination survey 2007- 2010). Am J Cardiol. 2013; 112 ( 8 ): 1126 - 1132.
dc.identifier.citedreferenceVulic D, Lee BT, Dede J, Lopez VA, Wong ND. Extent of control of cardiovascular risk factors and adherence to recommended therapies in US multiethnic adults with coronary heart disease: from a 2005- 2006 national survey. Am J Cardiovasc Drugs. 2010; 10 ( 2 ): 109 - 114.
dc.identifier.citedreferenceMa J, Sehgal NL, Ayanian JZ, Stafford RS. National trends in statin use by coronary heart disease risk category. PLoS Med. 2005; 2 ( 5 ): e123.
dc.identifier.citedreferencePeters SAE, Colantonio LD, Zhao H, et al. Sex differences in high- intensity statin use following myocardial infarction in the United States. J Am Coll Cardiol. 2018; 71 ( 16 ): 1729 - 1737.
dc.identifier.citedreferenceVatcheva KP, Aparicio V, Araya A, Gonzalez E, Laing ST. Statin prescription for patients with atherosclerotic cardiovascular Disease from National Survey Data. Am J Cardiol. 2019; 124 ( 1 ): 1 - 7.
dc.identifier.citedreferenceDorsch MP, Lester CA, Ding Y, Joseph M, Brook RD. Effects of race on statin prescribing for primary prevention with high atherosclerotic cardiovascular disease risk in a large healthcare system. J Am Heart Assoc. 2019; 8 ( 22 ): e014709.
dc.identifier.citedreferenceColantonio LD, Hubbard D, Monda KL, et al. Atherosclerotic risk and statin use among patients with peripheral artery disease. J Am Coll Cardiol. 2020; 76 ( 3 ): 251 - 264.
dc.identifier.citedreferenceMaddox TM, Borden WB, Tang F, et al. Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry. J Am Coll Cardiol. 2014; 64 ( 21 ): 2183 - 2192.
dc.identifier.citedreferenceMehta JL, Bursac Z, Mehta P, et al. Racial disparities in prescriptions for cardioprotective drugs and cardiac outcomes in veterans affairs hospitals. Am J Cardiol. 2010; 105 ( 7 ): 1019 - 1023.
dc.identifier.citedreferenceNanna MG, Navar AM, Zakroysky P, et al. Association of patient perceptions of cardiovascular risk and beliefs on statin drugs with racial differences in statin use: insights from the patient and provider assessment of lipid management registry. JAMA Cardiol. 2018; 3 ( 8 ): 739 - 748.
dc.identifier.citedreferenceKaralis DG, Wild RA, Maki KC, et al. Gender differences in side effects and attitudes regarding statin use in the understanding statin use in America and gaps in patient education (USAGE) study. J Clin Lipidol. 2016; 10 ( 4 ): 833 - 841.
dc.identifier.citedreferenceMefford MT, Tajeu GS, Tanner RM, et al. Willingness to be reinitiated on a statin (from the REasons for geographic and racial differences in stroke study). Am J Cardiol. 2018; 122 ( 5 ): 768 - 774.
dc.identifier.citedreferenceAarnio E, Martikainen J, Winn AN, Huupponen R, Vahtera J, Korhonen MJ. Socioeconomic inequalities in statin adherence under universal coverage: does sex matter? Circ Cardiovasc Qual Outcomes. 2016; 9 ( 6 ): 704 - 713.
dc.identifier.citedreferenceVirani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke Statistics- 2020 update: a report from the American Heart Association. Circulation. 2020; 141 ( 9 ): e139 - e596.
dc.identifier.citedreferenceWilkins JT, Ning H, Berry J, Zhao L, Dyer AR, Lloyd- Jones DM. Lifetime risk and years lived free of total cardiovascular disease. JAMA. 2012; 308 ( 17 ): 1795 - 1801.
dc.identifier.citedreferenceForce USPST, Bibbins- Domingo K, Grossman DC, et al. Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement. JAMA. 2016; 316 ( 19 ): 1997 - 2007.
dc.identifier.citedreferenceCollins R, Armitage J, Parish S, Sleigh P, Peto R. Heart protection study collaborative G. MRC/BHF heart protection study of cholesterol- lowering with simvastatin in 5963 people with diabetes: a randomised placebo- controlled trial. Lancet. 2003; 361 ( 9374 ): 2005 - 2016.
dc.identifier.citedreferenceMajor outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The antihypertensive and lipid- lowering treatment to prevent heart attack trial (ALLHAT- LLT). JAMA. 2002; 288 ( 23 ): 2998 - 3007.
dc.identifier.citedreferenceGrundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation. 2004; 110 ( 2 ): 227 - 239.
dc.identifier.citedreferenceStone NJ, Robinson JG, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129 ( 25 ): S1 - S45.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.